FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

_		
lashington,	D.C. 20549	

STATEMENT (OF CI	HANGES I	IN BENEFIC	CIAL OW	/NERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response.	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Wanstall Rick					2. Issuer Name and Ticker or Trading Symbol AILERON THERAPEUTICS INC [ALRN]						Chec	k all applica Director	able)	Perso	on(s) to Issue 10% Ow Other (s)	ner		
(Last) (First) (Middle) C/O AILERON THERAPEUTICS, INC. 285 SUMMER STREET, SUITE 101					3. Date of Earliest Transaction (Month/Day/Year) 03/30/2022						X Officer (give title Officer (specify below) See Remarks							
(Street) BOSTON	N M	MA 02210 (State) (Zip) 4. If Amendment, Date of Original Filed (Month/Day/Year) 03/24/2022						i. Indi ine) X	· .									
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			В	Execution Date,		Code (Instr.			4 and 5) Securitie Benefici		s Form ally (D) of following (I) (In		Direct Indirect Estr. 4)	7. Nature of ndirect Beneficial Ownership Instr. 4)				
								Code	٧	Amount	(A) or (D)		е	Transaction (Instr. 3 a	ction(s)			115(1.4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Security or Exercise (Month/Day/Year) if any Co		Transa	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and A of Securities Underlying Derivative Se (Instr. 3 and 4		ies g Security	Derivat Securit			ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)					
				Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Amoun or Numbe of Shar	.		(Instr. 4)	J.1(0)		
Stock Option (right to buy)	\$0.48	03/30/2022 ⁽¹⁾		A		393,000		(2)	0.	3/29/2032	Common Stock	393,0	00	\$0.00	393,00	0	D	

Explanation of Responses:

- 1. This amendment is being filed to correct the date of grant and the exercise price for the stock option reported on a Form 4 filed by the reporting person on March 24, 2022. This option became effective on March 30, 2022.
- 2. The shares underlying the option are scheduled to vest in equal monthly installments through March 30, 2026.

Remarks:

Chief Financial Officer and Treasurer

/s/ Richard Wanstall 03/30/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.